HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017

Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017

Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017

ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017

Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

Treatment Selection for HR+ mBC

October 2nd 2017

mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

October 2nd 2017

CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

October 2nd 2017

FDA Approval for Abemaciclib

October 2nd 2017

MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

October 2nd 2017

MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

October 2nd 2017

Abemaciclib + Fulvestrant at Progression of HR+ mBC

October 2nd 2017

Abemaciclib for ER+ mBC

October 2nd 2017

CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

October 2nd 2017

Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

CDK 4/6 Inhibitors in Metastatic Breast Cancer

October 2nd 2017